Meiji Yasuda Asset Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.83M | Buy |
53,418
+12,989
| +32% | +$1.09M | 0.22% | 140 |
|
|
2026
Q1 | $3.24M | Buy |
40,429
+35,363
| +698% | +$2.92M | 0.16% | 167 |
|
|
2025
Q4 | $432K | Buy |
+5,066
| New | +$416K | 0.02% | 358 |
|
|
2025
Q2 | – | Sell |
-9,435
| Closed | -$684K | – | 584 |
|
|
2025
Q1 | $684K | Sell |
9,435
-3,051
| -24% | -$218K | 0.03% | 367 |
|
|
2024
Q4 | $924K | Sell |
12,486
-265
| -2% | -$18.5K | 0.04% | 321 |
|
|
2024
Q3 | $841K | Sell |
12,751
-2,590
| -17% | -$188K | 0.03% | 335 |
|
|
2024
Q2 | $1.42M | Buy |
15,341
+184
| +1% | +$16.3K | 0.06% | 265 |
|
|
2024
Q1 | $1.45M | Buy |
15,157
+3,745
| +33% | +$315K | 0.06% | 259 |
|
|
2023
Q4 | $870K | Sell |
11,412
-745
| -6% | -$51.8K | 0.04% | 330 |
|
|
2023
Q3 | $842K | Buy |
12,157
+390
| +3% | +$31.3K | 0.04% | 351 |
|
|
2023
Q2 | $1.11M | Buy |
11,767
+989
| +9% | +$86K | 0.06% | 282 |
|
|
2023
Q1 | $892K | Buy |
10,778
+1,335
| +14% | +$105K | 0.05% | 303 |
|
|
2022
Q4 | $705 | Sell |
9,443
-380
| -4% | -$29.3K | 0.03% | 371 |
|
|
2022
Q3 | $812K | Sell |
9,823
-1,000
| -9% | -$96.2K | 0.05% | 331 |
|
|
2022
Q2 | $1.03M | Buy |
10,823
+770
| +8% | +$79.7K | 0.06% | 315 |
|
|
2022
Q1 | $1.18M | Sell |
10,053
-1,608
| -14% | -$180K | 0.06% | 299 |
|
|
2021
Q4 | $1.51M | Buy |
11,661
+1,041
| +10% | +$121K | 0.09% | 205 |
|
|
2021
Q3 | $1.2M | Buy |
10,620
+260
| +3% | +$29.7K | 0.09% | 223 |
|
|
2021
Q2 | $1.07M | Hold |
10,360
| – | – | 0.05% | 253 |
|
|
2021
Q1 | $867K | Buy |
10,360
+2,880
| +39% | +$243K | 0.06% | 265 |
|
|
2020
Q4 | $682K | Sell |
7,480
-400
| -5% | -$33.2K | 0.07% | 241 |
|
|
2020
Q3 | $629K | Sell |
7,880
-4,990
| -39% | -$389K | 0.07% | 235 |
|
|
2020
Q2 | $889K | Buy |
12,870
+4,500
| +54% | +$320K | 0.08% | 221 |
|
|
2020
Q1 | $526K | Sell |
8,370
-5,790
| -41% | -$418K | 0.1% | 171 |
|
|
2019
Q4 | $1.1M | Buy |
14,160
+600
| +4% | +$46.9K | 0.09% | 232 |
|
|
2019
Q3 | $994K | Hold |
13,560
| – | – | 0.08% | 260 |
|
|
2019
Q2 | $835K | Sell |
13,560
-1,935
| -12% | -$117K | 0.07% | 285 |
|
|
2019
Q1 | $988K | Hold |
15,495
| – | – | 0.08% | 254 |
|
|
2018
Q4 | $791K | Hold |
15,495
| – | – | 0.07% | 281 |
|
|
2018
Q3 | $899K | Hold |
15,495
| – | – | 0.07% | 264 |
|
|
2018
Q2 | $752K | Sell |
15,495
-4,485
| -22% | -$209K | 0.07% | 293 |
|
|
2018
Q1 | $929K | Hold |
19,980
| – | – | 0.09% | 253 |
|
|
2017
Q4 | $751K | Hold |
19,980
| – | – | 0.07% | 286 |
|
|
2017
Q3 | $728K | Hold |
19,980
| – | – | 0.07% | 285 |
|
|
2017
Q2 | $787K | Hold |
19,980
| – | – | 0.08% | 263 |
|
|
2017
Q1 | $627K | Buy |
19,980
+11,610
| +139% | +$363K | 0.07% | 300 |
|
|
2016
Q4 | $261K | Sell |
8,370
-1,650
| -16% | -$53.5K | 0.03% | 436 |
|
|
2016
Q3 | $403K | Buy |
10,020
+3,930
| +65% | +$148K | 0.05% | 354 |
|
|
2016
Q2 | $202K | Buy |
+6,090
| New | +$208K | 0.03% | 428 |
|
|
2014
Q4 | – | Sell |
-18,540
| Closed | -$316K | – | 351 |
|
|
2014
Q3 | $316K | Buy |
+18,540
| New | +$293K | 0.07% | 277 |
|
|
2014
Q2 | – | Sell |
-21,480
| Closed | -$266K | – | 361 |
|
|
2014
Q1 | $266K | Sell |
21,480
-12,780
| -37% | -$147K | 0.06% | 304 |
|
|
2013
Q4 | $375K | Buy |
34,260
+15,720
| +85% | +$177K | 0.08% | 230 |
|
|
2013
Q3 | $215K | Sell |
18,540
-6,480
| -26% | -$75.8K | 0.05% | 332 |
|
|
2013
Q2 | $279K | Buy |
+25,020
| New | +$296K | 0.07% | 270 |
|
Other funds holding EW
Meiji Yasuda Asset Management's EW Position: Q2 2026 in Review
Meiji Yasuda Asset Management increased its Edwards Lifesciences (EW) stake by 32% in Q2 2026, buying an estimated $1.09M and bringing the position to 53,418 shares worth $4.83M. The position accounts for 0.22% of the portfolio, ranked #140.
Meiji Yasuda Asset Management first reported a position in EW in Q2 2013 and has held it in 44 quarters since. 1,325 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Meiji Yasuda Asset Management held 53,418 shares of Edwards Lifesciences worth $4.83M as of Q2 2026.
- Meiji Yasuda Asset Management bought 12,989 Edwards Lifesciences shares in Q2 2026, an estimated $1.09M.
- Edwards Lifesciences made up 0.22% of Meiji Yasuda Asset Management's portfolio in Q2 2026, its #140 holding.
- Meiji Yasuda Asset Management first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 44 quarters since.
- 1,325 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Meiji Yasuda Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.